STOCK TITAN

Cue Health Inc. - HLTH STOCK NEWS

Welcome to our dedicated page for Cue Health news (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Cue Health stock.

Cue Health Inc. (HLTH) is a pioneering healthcare technology company that empowers individuals to manage their health with precision and convenience. Cue Health offers a revolutionary device that tracks key health and lifestyle indicators at the molecular level, including inflammation, vitamin D, fertility, influenza, and testosterone. This compact, user-friendly device enables consumers to perform these tests at home in just minutes.

The data collected by Cue is sent via Bluetooth 4.0 to the user’s smartphone, where the free Cue app provides an in-depth analysis of how activity, food, and sleep impact their health. By using noninvasive samples such as saliva, blood, or nasal swabs, users can access lab-quality information about their bodies on demand.

Recent Achievements:

  • The company has gained recognition for its innovative approach to personal health monitoring, making previously lab-exclusive data accessible to the general public.
  • Partnerships with leading healthcare providers have expanded the usability and integration of Cue devices.

Current Projects:

  • Continued development of advanced features within the Cue app, including interactive charts that help users visualize their health trends.
  • Research-based recommendations for foods proven to support optimal health tailored to the user's specific molecular data.

By offering a comprehensive tool for health management, Cue Health Inc. continues to play a significant role in transforming how individuals monitor and improve their well-being. The company’s dedication to providing accessible and real-time health data is a testament to its commitment to innovation and public health.

Rhea-AI Summary

Cue Health (Nasdaq: HLTH) has partnered with the Minnesota Department of Health to offer a COVID-19 telehealth-to-treatment program at no cost. This service allows Minnesota residents who test positive for COVID-19 to consult healthcare professionals virtually and obtain prescriptions for treatment. The program provides same-day treatment access through local pharmacies, regardless of insurance status. Cue's COVID-19 test is renowned for its accuracy, with a 97.8% concordance rate with PCR tests, making it a critical tool in pandemic response.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.54%
Tags
none
-
Rhea-AI Summary

Cue Health (Nasdaq: HLTH) has expanded its Board of Directors with the addition of Josh Ghaim, Ph.D., and Sachin Jain, M.D. This brings the total number of directors to seven, with five being independent. Ghaim is noted for his extensive experience in digital health and past role as Chief Technology Officer at Johnson & Johnson Consumer Health, while Jain is recognized for his leadership in healthcare innovation and current position as CEO of SCAN Group. This change aims to enhance Cue's strategic focus on making healthcare more accessible and timely.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
management
-
Rhea-AI Summary

Cue Health Inc. (Nasdaq: HLTH) reported Q3 2022 revenue of $69.6 million, surpassing expectations, driven largely by COVID-19 testing. The company submitted multiple tests for FDA clearance, including Flu A/B and a multiplex test for Flu A/B + COVID. Despite strong sales, Cue reported a GAAP net loss of $66.3 million and adjusted losses also reflected significant operational expenses of $86.4 million. Cash reserves stood at $304.7 million. Guidance for Q4 2022 forecasts revenue between $45 million and $50 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.47%
Tags
none
Rhea-AI Summary

Cue Health Inc. (Nasdaq: HLTH) will release its third quarter 2022 financial results on November 9, 2022. A conference call and webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent highlights. Investors can register for the live call online, and a replay will be available afterward on the company’s website. Cue Health, a healthcare technology company, specializes in accessible health information and diagnostics, with products including the first FDA-authorized at-home COVID-19 test.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Summary

Cue Health Inc. (Nasdaq: HLTH) partners with actress Jamie-Lynn Sigler to promote its Cue Care™ test-to-treatment service for COVID-19. This service allows individuals who test positive for COVID-19 to consult healthcare professionals virtually and receive prescription treatments delivered to their home through the Cue Health App. Cue and Sigler are donating Cue Readers and COVID-19 tests to the Multiple Sclerosis Association of America (MSAA), enabling home-testing for those at risk, particularly individuals with multiple sclerosis. Cue's COVID-19 test is recognized as the most accurate self-test in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.58%
Tags
partnership covid-19
-
Rhea-AI Summary

On September 27, 2022, Cue Health (Nasdaq: HLTH) appointed Suzanne Stone as its new Chief Commercial Officer. With over 25 years in the biotech and medical device sectors, Stone previously served as Senior Vice President at DexCom, where she managed nearly $2 billion in revenue. Her role at Cue will involve leading global commercial strategies and enhancing marketing initiatives. CEO Ayub Khattak emphasized the importance of her leadership in strengthening Cue's market position and growth in key customer categories.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
management
Rhea-AI Summary

Cue Health has appointed David Tsay, MD, PhD, as its new Chief Medical Officer. Dr. Tsay brings over 20 years of experience from his previous roles at Apple and New York-Presbyterian, where he led digital transformation initiatives. At Cue, he will define future diagnostic products and enhance collaboration across healthcare stakeholders. His expertise aims to advance Cue's mission of democratizing diagnostic testing, ultimately improving health outcomes. Cue Health, traded as HLTH, focuses on providing real-time health information and diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
management
-
Rhea-AI Summary

Cue Health (Nasdaq: HLTH) announced a de novo submission to the FDA for full clearance of its Cue® Flu Molecular Test, the first at-home flu test reviewed for safety and effectiveness. The clinical study indicated 99% accuracy compared to existing lab tests for influenza A&B. This test aims to facilitate early detection and treatment, aligning with Cue's strategy of innovation in diagnostics. The company's COVID-19 test remains under FDA de novo review. With over 250,000 Cue Readers in use, Cue Health is positioned as a leader in accessible health diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
-
Rhea-AI Summary

Cue Health (Nasdaq: HLTH) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:40 p.m. Eastern Time, in New York, NY. The event will be accessible via a live audio webcast and can be replayed for 180 days on the company’s website. Cue Health focuses on providing accessible health information and diagnostics, including a notable at-home COVID-19 test with FDA approval. Founded in 2010, the company is headquartered in San Diego.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
conferences
Rhea-AI Summary

On August 29, 2022, Cue Health Inc. (Nasdaq: HLTH) launched Cue Care™, a nationwide service providing same-day, at-home test-to-treatment solutions for COVID-19. Patients testing positive can consult healthcare professionals virtually, obtain e-prescriptions, and receive medication delivery, usually within hours, at a cost of $79 to $99. This service will soon extend to other diagnostic tests like flu and strep throat. Cue Health's COVID-19 test is noted for its accuracy, delivering results in 20 minutes and is endorsed by various prestigious organizations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
covid-19

FAQ

What is the current stock price of Cue Health (HLTH)?

The current stock price of Cue Health (HLTH) is $0.0434 as of June 5, 2024.

What is the market cap of Cue Health (HLTH)?

The market cap of Cue Health (HLTH) is approximately 6.9M.

What does Cue Health Inc. specialize in?

Cue Health Inc. specializes in providing a device that tracks key health and lifestyle indicators at the molecular level, enabling at-home testing and real-time health data analysis.

How does Cue's device work?

The device uses noninvasive samples such as saliva, blood, or nasal swabs to measure health indicators and sends the data via Bluetooth to the user’s smartphone for analysis.

What health indicators can Cue track?

Cue can track inflammation, vitamin D, fertility, influenza, and testosterone levels in just minutes at home.

What is the Cue app?

The Cue app is a free application that receives data from the Cue device and provides detailed insights into how activity, food, and sleep affect your health.

What recent achievements has Cue Health made?

Cue Health has been recognized for making lab-quality health data accessible at home and has formed partnerships with leading healthcare providers to enhance device usability.

What are some current projects at Cue Health?

Current projects include developing advanced app features like interactive health charts and offering personalized, research-based health recommendations.

How does Cue Health send data to a user's smartphone?

Cue Health uses Bluetooth 4.0 technology to send health data from the device to the user's smartphone.

Can the Cue device track trends in personal health?

Yes, the Cue app provides interactive charts that allow users to monitor their health trends over time and discover new patterns.

Is Cue Health's testing method invasive?

No, Cue Health uses noninvasive methods such as saliva, blood, or nasal swabs to collect health data.

What makes Cue Health unique?

Cue Health is unique in its ability to provide immediate, lab-quality health data at home, enabling users to make informed health decisions in real-time.

Cue Health Inc.

Nasdaq:HLTH

HLTH Rankings

HLTH Stock Data

6.90M
159.09M
11.57%
52.81%
0.49%
Health Information Services
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO